Depite successful primary percutaneous coronary intervention (PCI) and standardized medical treatment, prognosis of acute ST-elevation myocardial infarction patents are still a poor, with high morality and various complications such as heart failure. Roxadustat is a new drug targeting hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibition and has shown promising effect in reducing infarct size in pre-clinical studies.

This study aims to evaluate the efficacy and safety of early and short-term administration of roxadustat in the treatment of acute ST-elevation myocardial infarction.

This study is an open-label, paralleled, randomized controlled trial. It aims to evaluate the efficacy and safety of early and short-term administration of roxadustat in the treatment of acute ST-elevation myocardial infarction.

Inclusion Criteria:

• Acute STEMI (ST segment elevation myocardial infarction) diagnosed by ST elevation
• Coronary angiography within 12 hours of symptom onset, with TIMI flow grade 0 - 1 of culprit vessel
• Primary PCI with TIMI flow grade 2 - 3 after successful intervention
• Capable and willing to provide informed consent and capable of completing study visits

Exclusion Criteria:

• Previous acute myocardial infarction history
• Cardiogenic Shock at admission
• Previously treated by roxadustat
• Contraindications of roxadustat treatment
• Contraindication of Cardiac MRI (e.g. eGFR < 30 ml/min, pacemaker, metal prosthesis, etc.)

Qualified researchers can request access to anonymized individual patient-level data by contacting principle investigator of this study. Requests for IPD will be recieved, but this does not mean all requests will be shared by the investigators.

1 year after the end of this study

Please contact the investigators through email in the time frame.